Profile data is unavailable for this security.
About the company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
- Revenue in EUR (TTM)46.44bn
- Net income in EUR5.40bn
- Incorporated1994
- Employees87.99k
- LocationSanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
- Phone+33 153774000
- Fax+33 153774463
- Websitehttps://www.sanofi.com/
More ▼
Mergers & acquisitions
| Acquired company | SAN:PAR since announced | Transaction value |
|---|---|---|
| Mirati Therapeutics Inc | -17.14% | -- |
| Quten Research Institute LLC-Qunol | -12.81% | -- |
Data delayed at least 15 minutes, as of Apr 18 2024 16:39 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UCB SA | 5.25bn | 343.00m | 23.34bn | 9.08k | 68.16 | 2.54 | 22.57 | 4.44 | 1.76 | 1.76 | 26.91 | 47.30 | 0.3345 | 1.76 | 4.63 | 578,223.10 | 2.18 | 5.03 | 2.67 | 6.28 | 67.50 | 72.21 | 6.53 | 12.66 | 0.9224 | 3.14 | 0.2529 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Bayer AG | 47.64bn | -2.94bn | 25.78bn | 99.72k | -- | 0.7829 | 3.46 | 0.5412 | -2.99 | -2.99 | 48.49 | 33.52 | 0.3951 | 1.43 | 4.85 | 477,693.20 | -2.44 | -1.79 | -3.34 | -2.38 | 58.54 | 59.02 | -6.18 | -4.80 | 0.8015 | 3.40 | 0.5764 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
| HALEON PLC | 13.20bn | 1.23bn | 34.27bn | 24.00k | 28.47 | 1.79 | 47.77 | 2.60 | 0.1128 | 0.1128 | 1.22 | 1.80 | 0.3282 | 3.15 | 5.76 | 470,916.70 | 3.23 | -- | 3.73 | -- | 61.59 | -- | 9.83 | -- | 0.7349 | 7.37 | 0.3611 | -- | 4.09 | -- | -1.04 | -- | -- | -- |
| Lonza Group AG | 6.92bn | 673.50m | 39.13bn | 18.00k | 57.55 | 3.89 | 30.91 | 5.66 | 8.87 | 8.87 | 91.16 | 131.07 | 0.3928 | 2.80 | 5.84 | 373,166.70 | 3.83 | 5.07 | 4.64 | 6.21 | 29.00 | 39.15 | 9.75 | 14.52 | 1.20 | 11.86 | 0.2275 | 30.57 | 7.94 | 3.92 | -46.17 | -0.0306 | 23.95 | 7.78 |
| Merck KGaA | 20.99bn | 2.83bn | 63.80bn | 62.91k | 22.59 | 2.39 | 13.83 | 3.04 | 6.50 | 6.50 | 48.27 | 61.36 | 0.4327 | 1.86 | 5.03 | 333,709.50 | 5.84 | 5.64 | 7.20 | 7.27 | 59.03 | 61.86 | 13.49 | 12.97 | 0.8916 | 32.81 | 0.2694 | 9.26 | -5.57 | 7.19 | -15.09 | 21.40 | 14.77 | 11.97 |
| GSK plc | 35.43bn | 5.76bn | 76.68bn | 70.21k | 13.17 | 4.81 | 8.05 | 2.16 | 1.20 | 1.20 | 7.39 | 3.29 | 0.5091 | 1.57 | 4.20 | 431,949.00 | 8.91 | 6.74 | 13.91 | 10.71 | 72.42 | 70.29 | 17.50 | 16.93 | 0.624 | 10.99 | 0.5848 | 79.55 | 3.42 | -0.322 | 15.79 | 7.10 | 5.47 | -10.32 |
| Sanofi SA | 46.44bn | 5.40bn | 107.81bn | 87.99k | 19.82 | 1.44 | 13.96 | 2.32 | 4.30 | 4.30 | 37.04 | 59.17 | 0.3669 | 1.53 | 5.51 | 527,808.70 | 4.38 | 5.87 | 5.43 | 7.16 | 69.35 | 68.78 | 11.95 | 16.90 | 0.8675 | 66.19 | 0.1986 | 60.51 | 2.32 | 5.42 | -35.49 | 4.57 | 8.87 | 4.14 |
| Roche Holding AG | 60.47bn | 11.84bn | 185.19bn | 103.61k | 15.38 | 5.98 | 11.37 | 3.06 | 14.30 | 14.30 | 73.03 | 36.77 | 0.6574 | 1.91 | 5.19 | 566,729.40 | 13.84 | 16.12 | 20.84 | 25.24 | 73.39 | 71.48 | 21.05 | 22.98 | 1.04 | 20.77 | 0.4676 | 58.80 | -7.21 | 0.6494 | -7.43 | 1.90 | 10.01 | 1.99 |
| Novartis AG | 43.83bn | 8.05bn | 190.93bn | 76.06k | 22.54 | 4.07 | 11.89 | 4.36 | 3.76 | 6.52 | 20.37 | 20.82 | 0.4293 | 1.84 | 6.15 | 559,561.80 | 7.89 | 8.53 | 10.57 | 11.23 | 74.24 | 72.93 | 18.37 | 22.68 | 0.931 | 13.16 | 0.3605 | 67.20 | 7.57 | 0.2779 | 41.64 | -7.71 | 0.7808 | 6.19 |
| AstraZeneca plc | 43.04bn | 5.60bn | 197.85bn | 89.90k | 35.61 | 5.38 | 18.56 | 4.60 | 3.07 | 3.07 | 23.59 | 20.31 | 0.4637 | 1.59 | 4.05 | 409,791.90 | 6.03 | 3.34 | 8.47 | 4.61 | 82.39 | 79.64 | 13.01 | 7.69 | 0.6427 | 6.34 | 0.4222 | 143.06 | 3.29 | 15.71 | 81.11 | 22.54 | 22.47 | 1.10 |
| Novo Nordisk A/S | 31.13bn | 11.21bn | 397.15bn | 63.37k | 46.33 | 36.09 | 32.58 | 12.76 | 18.62 | 18.62 | 51.68 | 23.90 | 0.8359 | 1.27 | 4.03 | 3,665,157.00 | 30.12 | 29.17 | 63.12 | 58.62 | 84.60 | 83.93 | 36.03 | 33.55 | 0.6356 | -- | 0.2022 | 50.13 | 31.26 | 15.74 | 50.71 | 16.72 | 25.67 | 18.20 |
Data as of Apr 18 2024. Currency figures normalised to Sanofi SA's reporting currency: Euro EUR
14.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 41.04m | 3.25% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 25.80m | 2.04% |
| Dodge & Coxas of 31 Dec 2023 | 22.51m | 1.78% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 21.47m | 1.70% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 17.60m | 1.39% |
| Capital Research & Management Co. (World Investors)as of 04 Apr 2024 | 16.94m | 1.34% |
| BlackRock Advisors (UK) Ltd.as of 04 Apr 2024 | 13.14m | 1.04% |
| Capital International Ltd.as of 04 Apr 2024 | 10.60m | 0.84% |
| FIL Investments Internationalas of 05 Apr 2024 | 10.51m | 0.83% |
| Geode Capital Management LLCas of 11 Apr 2024 | 9.98m | 0.79% |
More ▼
Data from 31 Dec 2023 - 10 Apr 2024Source: FactSet Research Systems Inc.
